Feider Stephen 4/A
4/A · Beta Bionics, Inc. · Filed Jul 2, 2026
Research Summary
AI-generated summary of this filing
Beta Bionics (BBNX) CFO Stephen Feider Exercises Options and Sells Shares
What Happened
Stephen Feider, Chief Financial Officer of Beta Bionics (BBNX), exercised stock options to acquire a total of 10,000 shares (5,104 on 2026‑06‑26 and 4,896 on 2026‑06‑29) at an exercise price of $5.10 per share (cost ≈ $51,000). He then sold those same 10,000 shares in open‑market transactions under a Rule 10b5‑1 plan for total gross proceeds of about $170,387 (sales: 5,104 shares at an average ≈ $17.0468 on 6/26 for $87,006; 4,896 shares at an average ≈ $17.0304 on 6/29 for $83,381). This filing is an amendment to correct the number of shares and post‑transaction holdings.
Key Details
- Transaction dates and prices:
- 2026‑06‑26: Exercised 5,104 options @ $5.10 (acquired) and sold 5,104 shares at weighted avg $17.0468 (range $17.00–$17.12).
- 2026‑06‑29: Exercised 4,896 options @ $5.10 (acquired) and sold 4,896 shares at weighted avg $17.0304 (range $17.00–$17.08).
- Proceeds/costs: Sale proceeds ≈ $170,387; exercise cost ≈ $51,000.
- Shares owned after transaction: Not specified in the excerpt of this filing provided here.
- Notable footnotes:
- Sales were made pursuant to a Rule 10b5‑1 trading plan adopted May 15, 2025 (F2).
- The Form 4 was amended to correct the number of shares subject to the June 26 exercise and the post‑transaction beneficial ownership (F1).
- Weighted average sale prices and price ranges are listed; the filing notes full price breakdowns are available on request (F3, F4).
- The options vest monthly over 48 months beginning Sept 14, 2023 (F5).
- Derivative entries showing $0.00 disposed: these reflect termination/cancellation of option instruments upon exercise (reported as derivative disposition).
Context
This was an option exercise immediately followed by an open‑market sale of the acquired shares — a common pattern when insiders exercise options and use prearranged 10b5‑1 plans to sell shares. Such sales typically represent liquidity events rather than a direct signal about company prospects. The filing is amended to correct previously reported numbers; consult the full amended Form 4 for the post‑transaction beneficial ownership details.
Insider Transaction Report
- Exercise/Conversion
Common Stock
[F1]2026-06-26$5.10/sh+5,104$26,030→ 171,157 total - Sale
Common Stock
[F2][F3][F1]2026-06-26$17.05/sh−5,104$87,006→ 166,053 total - Exercise/Conversion
Common Stock
[F1]2026-06-29$5.10/sh+4,896$24,970→ 170,949 total - Sale
Common Stock
[F2][F4][F1]2026-06-29$17.03/sh−4,896$83,381→ 166,053 total - Exercise/Conversion
Employee Stock Option (right to buy)
[F1][F5]2026-06-26−5,104→ 44,591 totalExercise: $5.10Exp: 2033-09-13→ Common Stock (5,104 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
[F5][F1]2026-06-29−4,896→ 39,695 totalExercise: $5.10Exp: 2033-09-13→ Common Stock (4,896 underlying)
Footnotes (5)
- [F1]This Form 4 is being amended to correct the number of shares subject to the option exercise that occurred on June 26, 2026, in connection with the reported sales and to correct the number of securities beneficially owned following the reported transactions.
- [F2]Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025.
- [F3]The weighted average sale price for the transaction reported was $17.046782 and the range of prices were between $17 and $17.12. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F4]The weighted average sale price for the transaction reported was $17.0304 and the range of prices were between $17 and $17.08. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F5]The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023.